Special Drug Use Investigation (Retrospective) for Arixtra® (Fondaparinux) Venous Thromboembolism Treatment (Over 100kg)

GlaxoSmithKline (GSK)

Status: Completed

Conditions: Ataxia

Treatments: Drug: Fondaparinux sodium

Study type: Observational

Funder types: Industry

Identifiers

NCT01428544

115490

Details and patient eligibility

About

The purpose of this post-marketing surveillance study is to collect and assess information retrospectively on safety and effectiveness of fondaparinux injection in patients with venous thromboembolism (VTE) whose body weight is 100 kilograms (kg) or more, or to whom fondaparinux was injected 10 mg/day.

("Arixtra" is a trademark of the GlaxoSmithKline group of companies.)

Enrollment: 5 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with acute pulmonary thromboembolism or acute deep venous thrombosis
• Fondaparinux injection must be prescribed for the first time

Exclusion criteria

• Not applicable

Trial design

5 participants in 1 patient group

Patients with VTE treated with fondaparinux

Description:

Patients with VTE treated with fondaparinux

Treatment:

Drug: Fondaparinux sodium